Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2141-2148

  Wang, Li ^a   Raju, Uma ^a   Milas, Luka ^a   Molkentine, David ^a   Zhang, Zhen ^b   Yang, Peiying ^a   Cohen, Lorenzo ^a   Meng, Zhiqiang ^b   Liao, Zhongxing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Clonogenic cell survival; Huachansu; Inhibition of DNA repair; Lung cancer cells; Radiation sensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIAC GLYCOSIDE; CASPASE 3; HISTONE H2AX; HUACHANSU; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IRRADIATION; LUNG CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPLETION; RADIOSENSITIVITY; WESTERN BLOTTING;

AMPHIBIAN VENOMS; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONES; HUMANS; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 79960469869     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC and Rosenman JG: Induction and concurrent chemotherapy with high-dose thoracic conformai radiation therapy in unresectable stage IIIA and IIIB non small cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22: 4341-4350, 2004.
2. Wang L, Correa CR, Zhao L, Hayman J, Kalemkerian GP, Lyons S, Cease K, Brenner D and Kong FM: The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 73: 1383-1390, 2009.
3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
4. Curran W, Scott C, Langer C, Komaki R, Lee JS, Rosenthal S, Byhardt R, Sause W and Cox JD: Phase III comparison of sequential vs. concurrent chemoradiation for patients with non-small cell lung cancer (NSCLC): initial report of RTOG 9410. Proc Am Soc Clin Oncol 19: abstr 1891, 2000.
5. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR Jr., Moran C, Allen PK and Komaki R: Comparison of outcomes for patients with unresectable, locally advanced non small cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68: 779-785, 2007. (Pubitemid 46818738)
6. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356, 2002. (Pubitemid 36025259)
7. Zhang P, Cui Z, Liu Y, Wang D, Liu N and Yoshikawa M: Quality evaluation of traditional Chinese drug toad venom from different origins through a simultaneous determination of bufogenins and indole alkaloids by HPLC. Chem Pharm Bull (Tokyo) 55: 1582-1586, 2005. (Pubitemid 41744489)
8. Dai LP, Wang ZM, Gao HM, Jiang X and Ding GZ: Determination of bufothionine in skin of Bufo bufo gargarizans and HCS injection. Zhongguo Zhongyao Zazhi 32: 224-226, 2007 (in Chinese).
9. Qin TJ, Zhao XH and Yun J: Efficacy and safety of gemcitabine-oxaliplatin combined with HCS in patients with advanced gallbladder carcinoma. World J Gastroenterol 14: 5210-5216, 2008.
10. Ye M, Qu G, Guo H and Guo D: Specific 12 beta-hydroxylation of cinobufagin by filamentous fungi. Appl Environ Microbiol 70: 3521-3527, 2004. (Pubitemid 38745899)
11. Ma XC, Xin XL, Liu KX, Han J and Guo DA: Microbial transformation of cinobufagin by Syncephalastrum racemosum. J Nat Prod 71: 1268-1270, 2008.
12. Ye M, Guo H, Guo H, Han J and Guo D: Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. J Chromatogr B Analyt Technol Biomed Life Sci 838: 86-95, 2006. (Pubitemid 43946741)
13. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z and Kurzrock R: Pilot study of HCS in patients with hepatocellular carcinoma, no-small cell lung cancer, or pancreatic cancer. Cancer 115: 5309-5318, 2009.
14. Su YH and Nu X: Evaluation of pharmacodynamic effect of pharmaceutical agents of Chan Su. J Beijing Univ TCM 24: 51-54, 2001(Article in Chinese).
15. Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie JM and Linh CQ: HPLC separation and determination of bufadienolide in cinobufacini injection. Chin Tradit Pat Med 25: 24-27, 2003.
16. Watabe M, Masudo Y, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 271: 14067-14072, 1996.
17. Yeh JY, Huang WJ, Kan SF and Wang PS: Effects of bufalin and cinobufagin on the proliferation of androgen-dependent and -independent prostate cancer cells. Prostate 54: 112-124, 2003. (Pubitemid 36120327)
18. Han KQ, Huang G, Gu W, Su YH, Huang XQ and Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J. Gastroenterol 13: 3374-3379, 2007. (Pubitemid 47062250)
19. Kamano Y, Nogawa T, Yamashita A, Hayashi M and Inoue M: Isolation and structure of a 20,21 epoxybufenolide series from 'Ch'an Su'. J Nat Prod 65: 1001-1005, 2002.
20. Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
21. Hashimoto S, Jing Y and Kawazoe N: Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res 21: 875-883, 1997. (Pubitemid 27488715)
22. +-ATPase mediated signal transduction: from protein interaction to cellular function. Mol Interv 5: 157-168, 2003.
23. Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism and cell growth. Am J Physiol. Cell Physiol 293: C509-536, 2007.
24. Watabe M and Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Treatment of U937 cells with bufalin induces the translation of casein kinase 2 and modulates the activity of topoisomerase II prior to induction of apoptosis. Cell Growth Differ 8: 871-879, 1997. (Pubitemid 27355460)
25. 1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Human Reprod 11: 817-823, 2005. (Pubitemid 43205490)
26. Newman RA, Yang P, Pawlus AD and Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49, 2008.
27. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B and Schmid RA: Cardiac glycosides initiate Apo2L/TRAIL induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66: 5867-5874, 2006.
28. Numazawa S, Honna Y, Yamamoto T, Yoshida T and Kuroiwa Y: A cardiotonic steroid bufalin-like factor in human plasma induces leukemia cell differentiation. Leuk Res 19: 945-953, 1995. (Pubitemid 26037987)
29. Zhang L, Nakaya K, Yoshida T and Kuroiwa Y: Induction by bufalin of differentiation of human leukemia cells HL60, U937 and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 52: 4634-4641, 1992.
30. Verheye-Dua FA and Böhm, L: Influence of apoptosis on the enhancement of radiotoxicity by ouabain. Strahlenther Onkol 176: 186-191, 2000. (Pubitemid 30212063)
31. Verheye-Dua FA and Böhm L: Influence of cell inactivation by irradiation. Strahlenther Onkol 172: 156-161, 1996.
32. +-ATPase inhibitor, ouabain accentuates irradiation damage in human tumour cell lines. Radiat Oncol Investig 6: 109-119, 1998. (Pubitemid 28280519)
33. Lawrence TS: Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 15: 953-958, 1988.
34. Nasu S, Milas L, Kawabe S, Raju U and Newman RA: Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett 185: 145-151, 2002.
35. Lawrence TS and Davis MA: The influence of Na+,K(+)-pump blockade on doxorubicin-mediated cytotoxicity and DNA strand breakage in human tumor cells. Cancer Chemother Pharmacol 26: 163-167, 1990. (Pubitemid 20191190)
36. Pastor N and Cortés F: Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells. DNA Repair 2: 1353-1360, 2003. (Pubitemid 37464813)
37. Fertil B and Malaise EP: Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 7: 621-629, 1981. (Pubitemid 11072545)